Integra Short Term Debt vs Other Stockholder Equity Analysis
IART Stock | USD 24.54 0.84 3.54% |
Integra LifeSciences financial indicator trend analysis is infinitely more than just investigating Integra LifeSciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Integra LifeSciences is a good investment. Please check the relationship between Integra LifeSciences Short Term Debt and its Other Stockholder Equity accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Short Term Debt vs Other Stockholder Equity
Short Term Debt vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Integra LifeSciences Short Term Debt account and Other Stockholder Equity. At this time, the significance of the direction appears to have very week relationship.
The correlation between Integra LifeSciences' Short Term Debt and Other Stockholder Equity is 0.21. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Integra LifeSciences Holdings, assuming nothing else is changed. The correlation between historical values of Integra LifeSciences' Short Term Debt and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Integra LifeSciences Holdings are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Short Term Debt i.e., Integra LifeSciences' Short Term Debt and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.21 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Short Term Debt
Other Stockholder Equity
Most indicators from Integra LifeSciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Integra LifeSciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Integra LifeSciences' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 442.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 339.5 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 944.6M | 970.3M | 888.4M | 458.0M | Total Revenue | 1.5B | 1.6B | 1.5B | 1.6B |
Integra LifeSciences fundamental ratios Correlations
Click cells to compare fundamentals
Integra LifeSciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Integra LifeSciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.3B | 3.6B | 3.8B | 3.9B | 3.8B | 4.0B | |
Other Current Liab | 156.2M | 182.1M | 198.3M | 144.2M | 176.3M | 185.1M | |
Total Current Liabilities | 331.3M | 401.0M | 340.0M | 320.9M | 307.0M | 158.9M | |
Total Stockholder Equity | 1.4B | 1.5B | 1.7B | 1.8B | 1.6B | 1.7B | |
Property Plant And Equipment Net | 431.9M | 371.2M | 396.2M | 459.6M | 496.4M | 521.2M | |
Net Debt | 1.3B | 1.2B | 1.1B | 1.2B | 1.4B | 1.5B | |
Retained Earnings | 398.6M | 532.3M | 698.6M | 879.1M | 946.9M | 994.2M | |
Accounts Payable | 113.1M | 54.6M | 61.8M | 102.1M | 92.3M | 96.9M | |
Cash | 198.9M | 470.2M | 513.4M | 456.7M | 276.4M | 290.2M | |
Non Current Assets Total | 2.4B | 2.4B | 2.6B | 2.7B | 2.7B | 2.9B | |
Non Currrent Assets Other | 11.2M | 11.3M | 10.0M | (510.2M) | 27.5M | 28.9M | |
Cash And Short Term Investments | 198.9M | 470.2M | 513.4M | 456.7M | 309.1M | 324.6M | |
Net Receivables | 275.3M | 225.5M | 231.8M | 263.5M | 259.3M | 272.3M | |
Common Stock Shares Outstanding | 86.5M | 85.2M | 85.5M | 83.5M | 80.3M | 67.2M | |
Liabilities And Stockholders Equity | 3.3B | 3.6B | 3.8B | 3.9B | 3.8B | 4.0B | |
Non Current Liabilities Total | 1.6B | 1.7B | 1.8B | 1.8B | 1.9B | 2.0B | |
Inventory | 316.1M | 310.1M | 317.4M | 324.6M | 389.6M | 409.1M | |
Other Current Assets | 67.9M | 231.4M | 91.1M | 116.8M | 100.0M | 51.5M | |
Other Stockholder Equity | 1.1B | 1.1B | 1.0B | 914.1M | 655.2M | 467.2M | |
Total Liab | 1.9B | 2.1B | 2.1B | 2.1B | 2.2B | 2.3B | |
Property Plant And Equipment Gross | 431.9M | 371.2M | 711.1M | 789.3M | 863.8M | 907.0M | |
Total Current Assets | 858.2M | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B | |
Accumulated Other Comprehensive Income | (76.4M) | (74.1M) | (45.2M) | 10.3M | (15.1M) | (15.9M) | |
Intangible Assets | 1.0B | 989.4M | 1.1B | 1.1B | 1.1B | 1.1B | |
Short Long Term Debt Total | 1.5B | 1.7B | 1.7B | 1.6B | 1.7B | 1.8B | |
Common Stock Total Equity | 887K | 893K | 896K | 905K | 1.0M | 528.7K | |
Short Term Investments | 1.5M | 4.7M | 12K | 16.7M | 32.7M | 34.3M | |
Short Term Debt | 57.3M | 159.1M | 74.6M | 67.4M | 29.8M | 28.3M | |
Common Stock | 887K | 893K | 896K | 905K | 909K | 547.5K | |
Other Liab | 116.1M | 131.2M | 135.9M | 201.8M | 232.1M | 243.7M | |
Other Assets | 27.3M | 168.6M | 3.8B | 63.2M | 72.6M | 69.0M | |
Long Term Debt | 1.2B | 1.4B | 1.4B | 1.3B | 1.5B | 749.7M | |
Treasury Stock | (119.9M) | (235.1M) | (234.4M) | (362.9M) | (326.6M) | (310.2M) | |
Property Plant Equipment | 337.4M | 287.5M | 311.7M | 311.3M | 358.0M | 375.9M | |
Current Deferred Revenue | 4.8M | 5.3M | 5.3M | 7.3M | 8.5M | 5.3M | |
Good Will | 954.3M | 932.4M | 1.0B | 1.0B | 1.1B | 1.1B | |
Net Tangible Assets | (569.1M) | (406.9M) | (474.2M) | (361.1M) | (325.0M) | (341.2M) | |
Retained Earnings Total Equity | 398.6M | 532.3M | 698.6M | 879.1M | 1.0B | 1.1B | |
Long Term Debt Total | 1.2B | 1.4B | 1.4B | 1.3B | 1.5B | 1.0B | |
Capital Surpluse | 1.2B | 1.3B | 1.3B | 1.3B | 1.5B | 1.0B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.